Cellular inflammatory and anti-viral effects of BOLD-100, a novel therapeutic agent in development for COVID-19

Bold-100 is a promising new drug that has been studied as a treatment for cancer. Because of the way it works in cells, there is reason to believe that it may also help protect against infections with viruses like SARS-CoV2 (the cause of COVID-19). The purpose of this project is to study the effects of Bold-100 on cells derived from the human intestine, which are susceptible to SARS-CoV2 infection, to help determine the way the drug effects normal cellular functions and their response to viral infections. The results will help to define the potential of Bold-100 as an antiviral drug, as well as its potential uses for other diseases, including intestinal cancers and inflammatory bowel disease.

Faculty Supervisor:

Ted Steiner

Student:

William Rees

Partner:

Bold Therapeutics

Discipline:

Medicine

Sector:

Professional, scientific and technical services

University:

University of British Columbia